Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
8.61
+0.25 (2.99%)
At close: Jun 2, 2026, 4:00 PM EDT
8.50
-0.11 (-1.28%)
Pre-market: Jun 3, 2026, 7:38 AM EDT

Decoy Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
3.623.734.965.727.146.1
Research & Development
1.040.370.777.1715.848.55
Other Operating Expenses
-8.52--8.87-
Total Operating Expenses
4.6612.615.7312.8931.8414.65
Operating Income
-2.22-12.61-5.73-12.89-31.84-14.65
Interest Income
0.090.10.160.350.22-
Other Non-Operating Income (Expense)
----0.010.04
Total Non-Operating Income (Expense)
0.090.10.160.350.230.04
Pretax Income
-2.14-12.52-5.58-12.54-31.61-14.61
Net Income
-1.83-12.52-5.58-12.54-31.61-12.77
Net Income to Common
-1.83-12.52-5.58-12.54-31.61-12.77
Shares Outstanding (Basic)
000000
Shares Outstanding (Diluted)
000000
Shares Change (YoY)
108.27%20.93%3436.88%53.66%927.18%-
EPS (Basic)
0.40-129.10-69.54-5532.48-21423.60-88934.40
EPS (Diluted)
0.40-129.10-69.54-5532.48-21423.60-88934.40
EPS Growth
-99.92%-----
Shares Outstanding
0.530.530.0100.020.02
Free Cash Flow
-6.53-4.83-4.53-12.85-17.6-10.2
Free Cash Flow Per Share
-25.99-49.78-56.44-5666.37-11926.20-71016.30
EBITDA
-2.22-12.61-5.73-12.88-31.83-14.63
EBIT
-2.22-12.61-5.73-12.89-31.84-14.65